Hippocampal abnormalities of glutamate/glutamine, N-acetylaspartate and choline in patients with depression are related to past illness burden

Journal of Psychiatry and Neuroscience

Volumn 38, Issue 2, 2013, Pages 107-116

  de Diego Adeliño, Javier ^a,b   Portella, Maria J ^a,b   Gómez Ansón, Beatriz ^a,c   López Moruelo, Olga ^a,c   Serra Blasco, Maria ^a   Vives, Yolanda ^a   Puigdemont, Dolors ^a,b   Pérez Egea, Rosario ^a,b   Álvarez, Enric ^a,b   Pérez, Víctor ^a,b  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE SALUD MENTAL CIBERSAM   (Spain)

^c CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; BENZODIAZEPINE; CHOLINE; GLUTAMIC ACID; GLUTAMINE; N ACETYLASPARTIC ACID; NEUROLEPTIC AGENT; ASPARTIC ACID; N-ACETYLASPARTATE;

ADULT; ARTICLE; CEREBROSPINAL FLUID; CONTROLLED STUDY; DEPRESSION; FEMALE; GRAY MATTER; HAMILTON SCALE; HIPPOCAMPUS; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; METABOLITE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; RELAPSE; TEMPORAL LOBE; WHITE MATTER; ANALOGS AND DERIVATIVES; CASE CONTROL STUDY; COST OF ILLNESS; CROSS-SECTIONAL STUDY; METABOLISM; MIDDLE AGED; PROCEDURES;

ADULT; ASPARTIC ACID; CASE-CONTROL STUDIES; CHOLINE; COST OF ILLNESS; CROSS-SECTIONAL STUDIES; DEPRESSIVE DISORDER, MAJOR; FEMALE; GLUTAMIC ACID; GLUTAMINE; HIPPOCAMPUS; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED;

EID: 84874338334     PISSN: 11804882     EISSN: 14882434     Source Type: Journal    
DOI: 10.1503/jpn.110185     Document Type: Article

References (33)

1. Drevets WC, Price JL, Furey ML. Brain structural and functional abnormalities in mood disorders: implications for neurocircuitry models of depression. Brain Struct Funct 2008;213:93-118.
2. Campbell S, Macqueen G. The role of the hippocampus in the pathophysiology of major depression. J Psychiatry Neurosci 2004;29: 417-26.
3. Campbell S, Marriott M, Nahmias C, et al. Lower hippocampal volume in patients suffering from depression: a meta-analysis. Am J Psychiatry 2004;161:598-607.
4. Videbech P, Ravnkilde B. Hippocampal volume and depression: a meta-analysis of MRI studies. Am J Psychiatry 2004;161:1957-66.
5. McKinnon MC, Yucel K, Nazarov A, et al. A meta-analysis examining clinical predictors of hippocampal volume in patients with major depressive disorder. J Psychiatry Neurosci 2009;34:41-54.
6. Lucassen PJ, Müller MB, Holsboer F, et al. Hippocampal apoptosis in major depression is a minor event and absent from subareas at risk for glucocorticoid overexposure. Am J Pathol 2001;158:453-68.
7. Hercher C, Turecki G, Mechawar N. Through the looking glass: examining neuroanatomical evidence for cellular alterations in major depression. J Psychiatr Res 2009;43:947-61.
8. Yildiz-Yesiloglu A, Ankerst DP. Review of 1H magnetic resonance spectroscopy findings in major depressive disorder: a metaanalysis. Psychiatry Res 2006;147:1-25.
9. Yüksel C, Öngür D. Magnetic resonance spectroscopy studies of glutamate-related abnormalities in mood disorders. Biol Psychiatry 2010;68:785-94.
10. Boulanger Y, Labelle M, Khiat A. Role of phospholipase A(2) on the variations of the choline signal intensity observed by 1H magnetic resonance spectroscopy in brain diseases. Brain Res Brain Res Rev 2000;33:380-9.
11. Moffett JR, Ross B, Arun P, et al. N-Acetylaspartate in the CNS: from neurodiagnostics to neurobiology. Prog Neurobiol 2007;81:89-131.
12. Michael N, Erfurth A, Ohrmann P, et al. Neurotrophic effects of electroconvulsive therapy: a proton magnetic resonance study of the left amygdalar region in patients with treatment-resistant depression. Neuropsychopharmacology 2003;28:720-5.
13. Block W, Träber F, von Widdern O, et al. Proton MR spectroscopy of the hippocampus at 3 T in patients with unipolar major depressive disorder: correlates and predictors of treatment response. Int J Neuropsychopharmacol 2009;12:415-22.
14. Milne A, MacQueena GM, Yucela K, et al. Hippocampal metabolic abnormalities at first onset and with recurrent episodes of a major depressive disorder: a proton magnetic resonance spectroscopy study. Neuroimage 2009;47:36-41.
15. Mervaala E, Föhr J, Könönen M, et al. Quantitative MRI of the hip-pocampus and amygdala in severe depression. Psychol Med 2000; 30:117-25.
16. Ende G, Braus DF, Walter S, et al. The hippocampus in patients treated with electroconvulsive therapy: a proton magnetic resonance spectroscopic imaging study. Arch Gen Psychiatry 2000;57:937-43.
17. Pittenger C, Duman RS. Stress, depression, and neuroplasticity: a convergence of mechanisms. Neuropsychopharmacology 2008;33:88-109.
18. Portella MJ, de Diego-Adeliño J, Gómez-Ansón B, et al. Ventro medial prefrontal spectroscopic abnormalities over the course of depression: a comparison among first episode, remitted recurrent and chronic patients. J Psychiatr Res 2011;45:427-34.
19. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62.
20. Provencher SW. Automatic quantitation of localized in vivo 1H spectra with LCModel. NMR Biomed 2001;14:260-4.
21. Li BS, Wang H, Gonen O. Metabolite ratios to assumed stable creatine level may confound the quantification of proton brain MR spectroscopy. Magn Reson Imaging 2003;21:923-8.
22. Gruber S, Frey R, Mlynárik V, et al. Quantification of metabolic differences in the frontal brain of depressive patients and controls obtained by 1H MRS at 3 Tesla. Invest Radiol 2003;38:403-8.
23. Frye MA, Watzl J, Banakar S, et al. Increased anterior cingulate/medial prefrontal cortical glutamate and creatine in bipolar depression. Neuropsychopharmacology 2007;32:2490-9.
24. Brennan BP, Hudson JI, Jensen JE, et al. Rapid enhancement of glutamatergic neurotransmission in bipolar depression following treatment with riluzole. Neuropsychopharmacology 2010;35:834-46.
25. Yushkevich PA, Piven J, Hazlett HC, et al. User-guided 3D active contour segmentation of anatomical structures: Significantly improved efficiency and reliability. Neuroimage 2006;31:1116-28.
26. Resmini E, Santos A, Gómez-Anson B, et al. Verbal and visual memory performance and hippocampal volumes, measured by 3-Tesla magnetic resonance imaging, in patients with Cushing's syndrome. J Clin Endocrinol Metab 2012;97:663-71.
27. Stockmeier CA, Mahajan GJ, Konick LC, et al. Cellular changes in the postmortem hippocampus in major depression. Biol Psychiatry 2004;56:640-50.
28. Czéh B, Lucassen PJ. What causes the hippocampal volume decrease in depression? Are neurogenesis, glial changes and apoptosis implicated? Eur Arch Psychiatry Clin Neurosci 2007;257:250-60.
29. Reynolds LM, Reynolds GP. Differential regional N-acetylaspartate deficits in postmortem brain in schizophrenia, bipolar disorder and major depressive disorder. J Psychiatr Res 2011;45:54-9.
30. Yildiz-Yesiloglu A, Ankerst DP. Neurochemical alterations of the brain in bipolar disorder and their implications for pathophysiology: a systematic review of the in vivo proton magnetic resonance spectroscopy findings. Prog Neuropsychopharmacol Biol Psychiatry 2006;30:969-95.
31. MacMaster FP, Moore GJ, Russell A, et al. Medial temporal N-acetyl-aspartate in pediatric major depression. Psychiatry Res 2008; 164:86-9.
32. Czéh B, Michaelis T, Watanabe T, et al. Stress-induced changes in cerebral metabolites, hippocampal volume, and cell proliferation are prevented by antidepressant treatment with tianeptine. Proc Natl Acad Sci U S A 2001;98:12796-801.
33. van der Hart MG, Czéh B, de Biurrun G, et al. Substance P receptor antagonist and clomipramine prevent stress-induced alterations in cerebral metabolites, cytogenesis in the dentate gyrus and hippocampal volume. Mol Psychiatry 2002;7:933-41.